摘要
目的应用血清超敏C反应蛋白(hs-CRP)水平评价美托洛尔治疗心力衰竭患者的疗效。方法选取2011年12月至2012年12月收治的患者50例,给予酒石酸美托洛尔(倍他乐克)治疗前采用散射比浊法测定患者血清hs-CRP水平,应用美托洛尔治疗6月后检测血清hs-CRP水平并评价疗效。同时随机抽取40例健康体检者作为正常对照组,测定血清hs-CRP水平。结果治疗前,患者的血清hs-CRP水平明显高于正常组(P<0.05);治疗6个月后,患者的血清hs-CRP水平明显低于治疗前(P<0.05),但与正常组比较无明显差异(P<0.05)。同时美托洛尔治疗效果与血清超敏C反应蛋白水平有相关性,治疗效果达到显效的hs-CRP水平为(0.91±0.36)mg/L,达到有效的hs-CRP水平为(4.38±1.23)mg/L,无效患者的hs-CRP水平为(9.77±3.91)mg/L。结论通过检测血清hs-CRP水平,可以判断美托洛尔治疗心力衰竭的疗效,具有重要的临床价值,值得临床推广。
Objective To investigate the application of hypersensitive C reaction protein(hs - CRP)for evaluating the effect of metopro-lol in the treatment of heart failure. Methods 50 cases of heart failure treated in our hospital from December 2011 to December 2012 were selected. Before the metoprolol treatment,serum hs - CRP level was measured by using nephelometry method. After the metoprolol treatment for 6 months,the serum hs - CRP level was redetected and the efficacy was evaluated. Meanwhile 40 individuals with healthy physical examination as the control group were randomly selected for detecting serum hs - CRP level. Results The serum hs - CRP lev-el before treatment in the heart failure patients was significantly higher than that in the normal group,the difference was statistically significant( P < 0. 05);after 6 - month metoprolol treatment,the patient' s serum hs - CRP level in the patients was significantly lower than before treatment,the difference was statistically significant( P < 0. 05),but compared with the normal group,no significant difference existed( P > 0. 05). Meanwhile the curative effect of metoprolol had the correlation with serum hs - CRP level,the hs - CRP level was (0. 91 ± 0. 36)mg / L in reaching significant effect,(4. 38 ± 1. 23)mg / L in reaching effect and(9. 77 ± 3. 91)mg / L in the ineffective patients. Conclusion Detecting Hs - CRP level for evaluating the efficacy of metoprolol in the treatment of heart failure has important clinical value and deserves to be clinically promoted.
出处
《中国药业》
CAS
2014年第12期29-30,共2页
China Pharmaceuticals
